YOGARAJA GUGGULU IN THE MANAGEMENT OF MEDOROGA WITH SPECIAL REFERENCE TO DYSLIPIDEMIA: A RANDOMIZED OPEN-LABELLED CONTROLLED CLINICAL STUDY

Background & Objectives: Dyslipidemia is a disorder of lipoprotein metabolism characterized by abnormalities in serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and very-low-density lipoprotein (VLDL). In Ayurveda, the condition has been correlated with Medoroga, associated with Medo Dhatu Vriddhi and abnormality of Meda. The present study was undertaken to clinically evaluate the efficacy of Yogaraja Guggulu in the management of Medoroga with special reference to dyslipidemia and to compare its effect with Navaka Guggulu. Methods: A randomized, open-labelled, parallel-group, active-controlled clinical study was conducted in 30 subjects fulfilling the diagnostic criteria for dyslipidemia. Subjects were randomly allocated into Group A (n=15), was given Yogaraja Guggulu, and Group B (n=15), was given Navaka Guggulu. Both interventions were administered orally for 30 days, followed by a 15-day drug-free follow-up. Fasting serum lipid profile was assessed on Day 0, Day 30 and Day 45. Within-group analysis was performed using the Wilcoxon signed-rank test and between-group analysis using the Mann-Whitney U test. Effect size was also assessed. Results: Group A showed highly significant reductions in total cholesterol, LDL, VLDL and triglycerides after 30 days of intervention, while improvement in HDL was non-significant. Group B showed highly significant reductions in total cholesterol, LDL and triglycerides and a significant reduction in VLDL; improvement in HDL was non-significant. Changes between the groups were non-significant for all assessed lipid parameters at Day 30 and Day 45. The overall effect was reported as 46.76% in Group A and 43.18% in Group B. Conclusion: In the present study, Yogaraja Guggulu showed significant improvement in most lipid parameters within the group and showed no statistically significant difference in between the group comparison. The findings support further evaluation of Yogaraja Guggulu in larger clinical studies of Medoroga with special reference to dyslipidemia.